Literature DB >> 25005569

Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy.

Michael J Fallon1, Jessica N Heck2.   

Abstract

Stevens-Johnson syndrome/toxic epidermal necrolysis overlap is an acute hypersensitivity reaction that compromises the integrity of mucous membranes and cutaneous tissue. While the pathophysiology of this syndrome has not been fully elucidated, it is commonly associated with the medication use and carries a significant mortality risk of approximately 30%. No commonalities among causative medications have been identified, and determining the offending agent can be challenging. This case report describes fatal Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a patient after receiving his first cycle of allopurinol, rituximab, and bendamustine treatment for non-Hodgkin's B-cell lymphoma. An analysis of FDA Medwatch adverse reaction case reports involving allopurinol, rituximab, and bendamustine is also presented.
© The Author(s) 2014.

Entities:  

Keywords:  Rituximab; Steven’s–Johnson syndrome; allopurinol; bendamustine; toxic epidermal necrolysis; tumor lysis syndrome

Mesh:

Substances:

Year:  2014        PMID: 25005569     DOI: 10.1177/1078155214533368

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  4 in total

1.  Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.

Authors:  Liezel L Griffin; Laura Cove-Smith; Hana Alachkar; John A Radford; Rebecca Brooke; Kim M Linton
Journal:  JAAD Case Rep       Date:  2018-02-23

Review 2.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

3.  Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy.

Authors:  Cristina Scavone; Cristina Di Mauro; Rosanna Ruggiero; Francesca Futura Bernardi; Ugo Trama; Maria Luisa Aiezza; Concetta Rafaniello; Annalisa Capuano
Journal:  Drugs Real World Outcomes       Date:  2020-03

Review 4.  Hypersensitivity reactions to monoclonal antibodies: Classification and treatment approach (Review).

Authors:  Irena Pintea; Carina Petricau; Dinu Dumitrascu; Adriana Muntean; Daniel Constantin Branisteanu; Daciana Elena Branisteanu; Diana Deleanu
Journal:  Exp Ther Med       Date:  2021-07-03       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.